TauC3 Biologics
London · Founded 2019 · Incorporated in United Kingdom · 1 known investors
TauC3 Biologics is a biotechnology company developing therapies for neurodegenerative diseases, with a focus on tau-related and Alzheimer's disease drug discovery. It brings together drug development and neuroscience expertise to advance treatments for CNS disorders.
Founders & leadership
TauC3 Biologics was founded in 2019 by Daniel Chain and Daniel G. Chain.
DC
Daniel ChainCo-founder
DG
Daniel G. ChainFounder (biotechnology executive and scientist entrepreneur)
SP
Scott PollackScientific/Platform Leader
PM
Peter McGowanCFO
SV
Shafique ViraniNamed on SEC filing
JG
John GogolNamed on SEC filing
AJ
Andrew J. HeathChairman
BG
Bia GoncalvesDirector of Scientific Communications
Board
PS
AH
Andrew HeathBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$868.2K disclosed across 4 rounds · 2020–2022
▶$690KraisedMar 2022 · BiotechnologyRule 506(b)
▶$690KraisedMar 2022 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Parag SaxenaDirector
- John GogolDirector
- Daniel ChainExecutive Officer, Director
- Andrew HeathDirector
- Shafique ViraniDirector
- Offering amount
- $690K
- Amount sold
- $690K
- First sale
- Jan 2022
- Incorporated
- Other, United Kingdom, 2019
- Federal exemptions
- 06b
▶$18.7KraisedDec 2020 · 1 investors · BiotechnologyRule 506(b)
▶$18.7KraisedDec 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John GogolDirector
- Shafique ViraniDirector
- Andrew HeathDirector
- Daniel ChainExecutive Officer, Director
- Parag SaxenaDirector
- Offering amount
- $18.7K
- Amount sold
- $18.7K
- First sale
- Dec 2020
- Incorporated
- Other, United Kingdom, 2019
- Federal exemptions
- 06b
▶$11KraisedNov 2020 · 2 investors · BiotechnologyRule 506(b)
▶$11KraisedNov 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel ChainExecutive Officer, Director
- Andrew HeathDirector
- John GogolDirector
- Parag SaxenaDirector
- Shafique ViraniDirector
- Offering amount
- $500K
- Amount sold
- $11K
- First sale
- Oct 2020
- Incorporated
- Other, United Kingdom, 2019
- Federal exemptions
- 06b
▶$148.5KraisedNov 2020 · 4 investors · BiotechnologyRule 506(b)
▶$148.5KraisedNov 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel ChainExecutive Officer, Director
- Andrew HeathDirector
- Shafique ViraniDirector
- Parag SaxenaDirector
- John GogolDirector
- Offering amount
- $148.5K
- Amount sold
- $148.5K
- First sale
- Oct 2020
- Incorporated
- Other, United Kingdom, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with TauC3 Biologics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does TauC3 Biologics do?
- TauC3 Biologics is a biotechnology company developing therapies for neurodegenerative diseases, with a focus on tau-related and Alzheimer's disease drug discovery. It brings together drug development and neuroscience expertise to advance treatments for CNS disorders.
- Who founded TauC3 Biologics?
- TauC3 Biologics was founded by Daniel Chain, Daniel G. Chain in 2019.
- Who are TauC3 Biologics's investors?
- TauC3 Biologics's investors include Vedanta Capital.
- How much funding has TauC3 Biologics raised?
- TauC3 Biologics has disclosed $868.2K raised across 4 rounds.
- Where is TauC3 Biologics headquartered?
- TauC3 Biologics is headquartered in London.